239 related articles for article (PubMed ID: 7561092)
1. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.
Schlegel PG; Vaysburd M; Chen Y; Butcher EC; Chao NJ
J Immunol; 1995 Oct; 155(8):3856-65. PubMed ID: 7561092
[TBL] [Abstract][Full Text] [Related]
2. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
3. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
[TBL] [Abstract][Full Text] [Related]
4. Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers.
Eyrich M; Burger G; Marquardt K; Budach W; Schilbach K; Niethammer D; Schlegel PG
Biol Blood Marrow Transplant; 2005 May; 11(5):371-82. PubMed ID: 15846291
[TBL] [Abstract][Full Text] [Related]
5. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
[TBL] [Abstract][Full Text] [Related]
7. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras.
Brochu S; Baron C; Hétu F; Roy DC; Perreault C
J Immunol; 1995 Dec; 155(11):5104-14. PubMed ID: 7594519
[TBL] [Abstract][Full Text] [Related]
8. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
9. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.
Schultz KR; Paquet J; Bader S; HayGlass KT
Bone Marrow Transplant; 1995 Aug; 16(2):289-95. PubMed ID: 7581150
[TBL] [Abstract][Full Text] [Related]
10. Effect of graft-versus-host disease on anti-tumor immunity.
Schreiber KL; Forman J
J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
[TBL] [Abstract][Full Text] [Related]
11. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
[TBL] [Abstract][Full Text] [Related]
12. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
13. Repertoire analysis of CD8+ T cell responses to minor histocompatibility antigens involved in graft-versus-host disease.
Friedman TM; Gilbert M; Briggs C; Korngold R
J Immunol; 1998 Jul; 161(1):41-8. PubMed ID: 9647205
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
15. Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens.
Hamilton BL; Bevan MJ; Parkman R
J Immunol; 1981 Feb; 126(2):621-5. PubMed ID: 6450246
[TBL] [Abstract][Full Text] [Related]
16. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
[TBL] [Abstract][Full Text] [Related]
17. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
18. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
Jones SC; Friedman TM; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
20. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.
Friedman TM; Jones SC; Statton D; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Apr; 10(4):224-35. PubMed ID: 15077221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]